Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.62 |
| ▸ | BRD2 | P25440 | 6/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.59 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487 | 0.82 | NPC1 (0.69) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL16404612 | 0.79 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL16246450 | 0.79 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL980536 | 0.79 | MAP4K4 (0.76) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL1772573 | 0.78 | BRD4 (0.66) | BRD4BRD2CREBBPBRD3ERN1 | |
| Hydrochloric Acid SCHEMBL1016039 | 0.78 | MAP4K4 (0.73) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL5714189 | 0.78 | BRD4 (0.61) | BRD4BRD2CREBBPBRD3NPC1 | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.77 | BRD4 (1.00) | BRD4BRD2CREBBP | |
| SCHEMBL24726640 | 0.77 | BRD4 (0.78) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL10145031 | 0.77 | BRD4 (0.59) | BRD4BRD2CREBBPBRD3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050075-B | Biaryl ring BET inhibitor and synthetic method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117050075-A | Biaryl ring BET inhibitor and synthetic method and application thereof | 中国药科大学 | 2023-11-14 | — | — | CN | disclosed |
| US-11538999-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-12-27 | — | — | US | disclosed |
| CN-107540614-B | Heterocyclic compound and organic light emitting device including the same | 三星显示有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3263558-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021143729-A1 | COMPOUND, COMPOSITION AND FUNCTIONAL MOLECULE WITH MULTI-TARGET INHIBITING EFFECT AND USE THEREOF | 中国科学院上海药物研究所 | 2021-07-22 | — | — | WO | disclosed |
| EP-3263558-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Display Co., Ltd. (KR) | 2018-01-03 | — | — | EP | disclosed |
| US-20170373256-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-12-28 | — | — | US | disclosed |
| US-5128335-A | Antibiotics | MERCK & CO., INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0481662-A1 | 2-Heteroarylphenyl-carbapenem antibacterial agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11538999-B2 | Heterocyclic compound and organic light-emitting device including the same | CCNT1, CYP1A1, CRY1 | BRD4 688/4885BRD2 912/4885CREBBP 2966/4885 |
| US-20170373256-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CCNT1, CYP1A1, CRY1 | BRD4 688/4885BRD2 912/4885CREBBP 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.